Showing results (71-80 of 160) with videos related to
Sort By:
Pageof 16
Frontiers in Oncology|April 13, 2023
Real-world clinical practice and outcomes in treating stage III non-small cell lung cancer: KINDLE-Asia subsetKumar Prabhash, Daniel Shao Weng Tan, Ross A Soo, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 13, 2022
Continuation of Lorlatinib in ALK-Positive NSCLC Beyond Progressive DiseaseSai-Hong I Ou, Benjamin J Solomon, Alice T Shaw, et al.Future Oncology (London, England)|August 3, 2019
Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: updated analysis of the observational GioTag studyMaximilian J Hochmair, Alessandro Morabito, Desiree Hao, et al.Lung Cancer (Amsterdam, Netherlands)|February 22, 2025
Comparative effectiveness and safety of tislelizumab versus other anti-PD-(L)1 agents in first- and subsequent lines in locally advanced or metastatic non-small cell lung cancer: Systematic literature review and network meta-analysisNicolas Girard, Ji-Youn Han, Ross A Soo, et al.Therapeutic Advances in Medical Oncology|December 24, 2025
A cost-effectiveness analysis model of actionable genomic alteration testing strategies incorporating different modalities and sizes of next-generation sequencing panels in non-small-cell lung cancerYvonne L E Ang, Jian Chun Matthew Ong, Yiqing Huang, et al.Cancer Biology & Therapy|March 8, 2011
Low cytosine triphosphate synthase 2 expression renders resistance to 5-fluorouracil in colorectal cancerWen Lee Tan, Bhaskar Bhattacharya, Marie Loh, et al.Lung Cancer (Amsterdam, Netherlands)|April 2, 2021
Phase I results of S49076 plus gefitinib in patients with EGFR TKI-resistant non-small cell lung cancer harbouring MET/AXL dysregulationKeunchil Park, Gee-Chen Chang, Giuseppe Curigliano, et al.Molecular Cancer Therapeutics|August 15, 2012
Activation of IL-6R/JAK1/STAT3 signaling induces de novo resistance to irreversible EGFR inhibitors in non-small cell lung cancer with T790M resistance mutationSun Mi Kim, Oh-Joon Kwon, Yun Kyoung Hong, et al.Future Oncology (London, England)|October 20, 2018
Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: an observational studyMaximilian J Hochmair, Alessandro Morabito, Desiree Hao, et al.Lung Cancer (Amsterdam, Netherlands)|February 27, 2017
Significance of immune checkpoint proteins in EGFR-mutant non-small cell lung cancerRoss A Soo, Hye Ryun Kim, Bernadette Reyna Asuncion, et al.Pageof 16